{"publication_id":"24f229e0-b6b2-4735-912f-34831eeac380","traces":[{"claim_id":"claim_1","claim":"Evidence-honesty note: 15/21 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_2","claim":"This synthesis tests the thesis that evidence for Metformin Cancer Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_3","claim":"We synthesized evidence from 21 curated sources to evaluate metformin’s effects on cancer outcomes across observational cohorts, systematic reviews, and mechanistic studies.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_4","claim":"Animal-model lifespan extensions of around 5% (Anisimov 2008) co-exist with null findings in human trials, underscoring translational gaps in metformin’s anti-aging or anti-cancer promise.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_5","claim":"Evidence-abstraction note.** The 21 retained reference papers are not 21 independent primary clinical trials: 21 are review, indirect, mechanistic, or registered-protocol source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_6","claim":"This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_cancer_effects-v06-DAILY-2026-06-14T20-47-12Z`.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_7","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_8","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_9","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_10","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_11","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_12","claim":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_13","claim":"| Contextual Adjacent Evidence | n=13; claims=655 | no extracted directional signal in 10/13 sources | 6 indirect; 1 mechanistic; 1 protocol; 5 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_14","claim":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_15","claim":"13 included sources were assigned to this outcome class. Directional coding: mixed=1, null=10, unclear=2. Directness coding: indirect=6, mechanistic=1, protocol=1, review=5.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_16","claim":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_17","claim":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, review=1.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_18","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_19","claim":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_20","claim":"The curated corpus provides no long-duration randomized trials directly testing metformin’s impact on cancer-specific mortality in non-diabetic adults, creating a critical evidence gap for the headline synthesis. All sources addressing mortality (Orchard 2023; Xie 2025) enroll adults with type 2 diabetes, limiting external validity to populations where metformin’s metabolic effects may confound oncologic endpoints. This restriction precludes generalization to the broader oncology population where glycemic control is not the primary therapeutic target, particularly for cancers where diabetes prevalence is lower (e.g., melanoma or hematologic malignancies).","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_21","claim":"Single-source dominance characterizes several outcome domains, increasing the risk of overgeneralization from non-replicated findings.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_22","claim":"The corpus underrepresents key clinical endpoints and populations that are essential for a comprehensive risk–benefit assessment of metformin in oncology. Additionally, the enrolled populations skew heavily toward adults with metabolic syndrome (Pasanisi 2024) or obesity-related cancers (Hussain 2025), leaving populations with normal glucose tolerance or non-obesity-related malignancies underrepresented. This imbalance restricts the synthesis’s applicability to the broader cancer survivor population, where metabolic heterogeneity is substantial.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_23","claim":"For metformin cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_24","claim":"This synthesis maps 21 included sources on Metformin Cancer Effects across 6 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_25","claim":"Across 21 curated reference papers, the evidence base for Metformin Cancer Effects shows a context-dependent profile. Null findings dominate: contextual other, mortality survival. The Metformin Cancer Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_26","claim":"Prior reviews in the corpus (Rangraze 2025) emphasize convergent signals on Metformin Cancer Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_27","claim":"| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_28","claim":"| contextual adjacent evidence | 0 | 13 | mixed, null, unclear | direct interventional hard-endpoint gap |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_29","claim":"| immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_30","claim":"| mortality and survival | 0 | 2 | null | direct interventional hard-endpoint gap |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]}]}